and Becton Dickinson, and has received speaker fees from Celgene and Takeda Canada. No other disclosures are reported.

**Funding/Support:** This work was funded by the Canadian Partnership Against Cancer.

**Role of the Funder/Sponsor:** The Canadian Partnership Against Cancer was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.

**Additional Contributions:** The authors thank the many contributors to the Cancer Risk Management Model, a listing of whom may be found on the Cancerview.ca website.


**CORRECTION**

**Missing Middle Initial in Author’s Name:** In the Original Investigation titled “Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA,” published online November 10, 2015, and printed January 14, 2016, the middle initial was omitted from an author’s name. The correct author name is David M. Hyman, MD. This article has been corrected online.


**Error in Corresponding Author Address:** In the Original Investigation titled “Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial,” published online November 25, 2015, there was an error in the address of the corresponding author. The correct address is “MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, England.” This article was corrected online.